Aled Edwards

From Wikipedia, the free encyclopedia

This article needs additional citations for verification.
Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (March 2007)

Aled Edwards Ph.D. is a noted Canadian structural biologist. He is also the Director and CEO of the international Structural Genomics Consortium and is Banbury Professor at the Banting and Best Department of Medical Research, the University of Toronto, Canada. Edwards has been a leader in the field of structural proteomics since the 1990s. His research group, in collaboration with the groups of University of Toronto biophysicists, Cheryl Arrowsmith and Emil F. Pai, have determined the structures of hundreds of proteins or protein fragments which are publicly accessible at the RCSB database.

Edwards received his PhD in biochemistry at McGill University in 1988 and conducted post-doctoral research in the laboratory of Prof. Roger Kornberg at Stanford University, 2006 Nobel Laureate in Chemistry.

While most structural biologists pursue structures of individual proteins or protein groups, specialists in structural proteomics, such as Edwards, pursue structures of proteins on a proteome wide scale. This implies large scale cloning, expression and purification. One main advantage of this approach is economy of scale. On the other hand, the scientific value of some resultant structures is at times questioned. Put another way, while the average cost of a protein structure is less than that incurred in a lab pursuing a small number of proteins, the balance in accounting shifts if only significant structures are counted. In short, the field of structural genomics has a significant number of supporters. An interesting Science article from January 2006 analyzes the structural genomics field.

Edwards was also one of the founders of Affinium Pharmaceuticals, a Toronto-based structure-guided drug discovery company. Edwards also serves as a scientific advisor on the television series ReGenesis.

Edwards has also spoken out against the current state of drug discovery research, highlighting the dearth of new drugs and the increasing cost of drug development. He is advocating an approach which utilizes academic research more in the early stages of the pipeline and focuses industrial efforts on pharmocology and clinical trials.